BR112015022972A2 - composição farmacêutica de cloridrato de s-cetamina - Google Patents

composição farmacêutica de cloridrato de s-cetamina

Info

Publication number
BR112015022972A2
BR112015022972A2 BR112015022972A BR112015022972A BR112015022972A2 BR 112015022972 A2 BR112015022972 A2 BR 112015022972A2 BR 112015022972 A BR112015022972 A BR 112015022972A BR 112015022972 A BR112015022972 A BR 112015022972A BR 112015022972 A2 BR112015022972 A2 BR 112015022972A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
ketamine hydrochloride
hydrochloride pharmaceutical
ketamine
formulation
Prior art date
Application number
BR112015022972A
Other languages
English (en)
Other versions
BR112015022972B1 (pt
Inventor
D G Basstanie Esther
Bentz Johanna
Rudolph Niemeijer Nico
C A Embrechts Roger
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50687638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015022972(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112015022972A2 publication Critical patent/BR112015022972A2/pt
Publication of BR112015022972B1 publication Critical patent/BR112015022972B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

resumo patente de invenção: "composição farmacêutica de cloridrato de s-cetamina". a presente invenção se refere a uma formulação aquosa de cloridrato de s-cetamina, de preferência, para administração nasal, em que a formulação não contém um conservante antimicrobiano.
BR112015022972-7A 2013-03-15 2014-03-14 Composição farmacêutica de cloridrato de s-cetamina e formas de dosagem da mesma BR112015022972B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791237P 2013-03-15 2013-03-15
US61/791,237 2013-03-15
PCT/US2014/027059 WO2014152196A1 (en) 2013-03-15 2014-03-14 Pharmaceutical composition of s-ketamine hydrochloride

Publications (2)

Publication Number Publication Date
BR112015022972A2 true BR112015022972A2 (pt) 2017-07-18
BR112015022972B1 BR112015022972B1 (pt) 2023-02-14

Family

ID=50687638

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022972-7A BR112015022972B1 (pt) 2013-03-15 2014-03-14 Composição farmacêutica de cloridrato de s-cetamina e formas de dosagem da mesma

Country Status (16)

Country Link
US (5) US20140275278A1 (pt)
EP (2) EP2968122B1 (pt)
KR (1) KR102217616B1 (pt)
CN (2) CN111643449A (pt)
AU (2) AU2014240102A1 (pt)
BR (1) BR112015022972B1 (pt)
CL (1) CL2015002736A1 (pt)
CR (1) CR20150481A (pt)
ES (2) ES2911466T3 (pt)
MX (1) MX371392B (pt)
MY (1) MY180526A (pt)
NI (1) NI201500135A (pt)
PE (1) PE20200404A1 (pt)
PH (1) PH12015502013B1 (pt)
SG (2) SG10201802104QA (pt)
WO (1) WO2014152196A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3043785T1 (sl) 2013-09-13 2022-02-28 National University Corporation Chiba University Uporaba R-ketamina in njegove soli kot farmacevtska sredstva
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
WO2017139382A1 (en) * 2016-02-08 2017-08-17 The Texas A&M University System Combination of adjuvant drugs esketamine and brimonidine for medical treatments
US20180177744A1 (en) * 2016-12-22 2018-06-28 Gary Jay Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
AU2019262197A1 (en) 2018-05-04 2020-11-26 Perception Neuroscience, Inc. Methods of treating substance abuse
US11154537B2 (en) 2018-08-10 2021-10-26 Eleusis Therapeutics Us, Inc. Method of treatment for ketamine infusion
EP3628313A1 (en) 2018-09-28 2020-04-01 Celon Pharma S.A. Ketamine composition for use in a method of treatment of depression by pulmonary administration
BR112021017457A2 (pt) 2019-03-05 2021-11-16 Janssen Pharmaceuticals Inc Escetamina para o tratamento de depressão
BR112021024138A2 (pt) 2019-05-31 2022-01-11 Celon Pharma Sa Sistema para administração supervisionada eletronicamente de uma composição farmacêutica
KR20220016484A (ko) 2019-05-31 2022-02-09 셀론 파르마 에스.에이. 약학적 조성물의 전자적으로 관리된 비경구 투여용 흡입기
EP3976012B1 (en) 2019-05-31 2024-03-20 Afyx Therapeutics A/S Intranasal administration of ketamine to cluster headache patients
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
CN114306218B (zh) * 2020-09-30 2023-11-10 四川普锐特药业有限公司 满足药学抑菌要求的经粘膜给药r-氯胺酮药物组合物
CN113813250B (zh) * 2021-07-21 2023-05-05 广州新济药业科技有限公司 含氯胺酮的药物组合物及其制备方法和应用
CN116942648A (zh) * 2022-04-26 2023-10-27 宜昌人福药业有限责任公司 艾司氯胺酮液体制剂及其用途

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
DE4312016A1 (de) * 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
AU733284B2 (en) 1995-02-24 2001-05-10 Stuart L. Weg Nasal and ocular administration of ketamine to manage pain and for detoxification
CA2230690C (en) 1995-08-30 2008-12-23 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
FR2739294B1 (fr) 1995-09-29 1998-01-16 Lhd Lab Hygiene Dietetique Embout nasal de securite
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
FR2764807B1 (fr) 1997-06-18 1999-08-20 Valois Sa Dispositif de distribution nasale d'un produit fluide ou pulverulent
WO2000004875A2 (en) * 1998-07-24 2000-02-03 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US6599883B1 (en) 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
CA2423354C (en) 2000-09-20 2009-12-15 Lee Shahinian Jr. Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US6881731B1 (en) 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
EP1551393A4 (en) 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
ATE432697T1 (de) 2002-11-18 2009-06-15 Yaupon Therapeutics Inc Analgetische verwendung von (s)-norketamin
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US8082173B2 (en) 2003-05-22 2011-12-20 Cecil Kost Drug sample fulfillment architecture
US20040265364A1 (en) 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US20050095277A1 (en) 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20060223788A1 (en) 2005-03-29 2006-10-05 Cathcart Clifton H Analgesic composition for topical use
JP5026411B2 (ja) 2005-06-01 2012-09-12 エスエイチエル グループ エービー 薬物送達装置
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
WO2007111880A2 (en) * 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
US20070256688A1 (en) 2006-04-21 2007-11-08 Aradigm Corporation Mechanical single dose intrapulmonary drug delivery devices
JP2009538331A (ja) 2006-05-22 2009-11-05 ヴァンダ ファーマシューティカルズ インコーポレイテッド 抑うつ障害のための治療
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US7745665B2 (en) 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
US8710070B2 (en) 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
CA2724277A1 (en) * 2008-05-13 2009-11-19 Clarassance, Inc. Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
PT2582366E (pt) 2010-06-15 2016-01-26 Gruenenthal Gmbh Combinação terapêutica para o tratamento da dor
WO2013003669A2 (en) 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
ES2886361T3 (es) 2011-10-14 2021-12-17 The Us Secretary Department Of Health & Human Services Uso de (2R,6R)-hidroxinorketamina y otros metabolitos hidroxilados estereoisómeros de (R,S)-ketamina en el tratamiento de depresión y dolor neuropático
RU2622082C2 (ru) 2011-11-14 2017-06-09 Нестек С.А. Анализы и способы выбора режима лечения пациента с депрессией
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
CN104519878A (zh) 2012-03-12 2015-04-15 詹森药业有限公司 用于治疗顽固性或难治性抑郁症的艾氯胺酮
AU2016203771A1 (en) 2012-03-13 2016-06-23 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015512418A (ja) 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
WO2014020155A1 (en) 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
EP2887930A4 (en) 2012-08-23 2016-03-23 Stuart L Weg ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
NZ619257A (en) 2012-10-08 2015-07-31 Auckland Uniservices Ltd Ketamine derivatives
ES2484068B1 (es) 2013-02-08 2015-04-16 Ana MÍNGUEZ MARTÍ Una composición farmacéutica que contiene ketamina y amitriptilina
US20160067196A1 (en) 2013-04-12 2016-03-10 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
EP3035918B1 (en) 2013-08-26 2021-06-30 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
SI3043785T1 (sl) 2013-09-13 2022-02-28 National University Corporation Chiba University Uporaba R-ketamina in njegove soli kot farmacevtska sredstva
US9569220B2 (en) 2013-10-06 2017-02-14 Synopsys, Inc. Processor branch cache with secondary branches
CN103705909A (zh) 2013-12-16 2014-04-09 陈镜伊 一种无痛人流用药
WO2015101693A1 (es) 2013-12-31 2015-07-09 Servicio Andaluz De Salud Composiciones y preparaciones combinadas para el tratamiento de las algias orofaríngeas
ES2726223T3 (es) 2014-01-14 2019-10-02 Childrens Hospital Med Ct Composiciones que comprenden ketamina para el tratamiento de un trastorno del espectro autista
DK3272338T3 (da) 2014-04-17 2020-11-02 Develco Pharma Schweiz Ag Oral doseringsform for ketamin
PE20171642A1 (es) 2014-05-04 2017-11-09 Firmenich & Cie Alimentos y bebidas saborizados
FR3023188B1 (fr) 2014-07-04 2016-08-19 Aptar France Sas Dispositif de distribution de produit fluide.
CA2957926A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
MA40620A (fr) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Régimes posologiques spécifiques au génotype val66met (snp rs6265) et méthodes pour le traitement de la dépression
US20180015054A1 (en) 2014-12-31 2018-01-18 Icahn School Of Medicine At Mount Sinai Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium
CN104798728A (zh) 2015-05-08 2015-07-29 南京中医药大学 产后抑郁动物模型的建立方法及其应用
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20180296478A1 (en) 2016-02-12 2018-10-18 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
US20180042936A1 (en) 2016-03-18 2018-02-15 Genomind, Inc. Maintenance therapy using tianeptine
CN112423789A (zh) 2017-12-22 2021-02-26 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮

Also Published As

Publication number Publication date
ES2755809T3 (es) 2020-04-23
AU2014240102A1 (en) 2015-09-17
AU2019200424B2 (en) 2020-05-14
US20200069612A1 (en) 2020-03-05
AU2019200424A8 (en) 2019-02-21
US20230241009A1 (en) 2023-08-03
US20140275278A1 (en) 2014-09-18
US20190117591A1 (en) 2019-04-25
CR20150481A (es) 2015-10-26
ES2911466T3 (es) 2022-05-19
MX371392B (es) 2020-01-28
AU2019200424A1 (en) 2019-02-14
US20140274981A1 (en) 2014-09-18
MY180526A (en) 2020-12-01
CN111643449A (zh) 2020-09-11
MX2015012617A (es) 2016-06-21
PE20200404A1 (es) 2020-02-26
PH12015502013A1 (en) 2016-01-11
SG11201507347QA (en) 2015-10-29
US11446260B2 (en) 2022-09-20
SG10201802104QA (en) 2018-05-30
CL2015002736A1 (es) 2016-03-28
EP2968122B1 (en) 2019-08-28
EP3636251A1 (en) 2020-04-15
WO2014152196A1 (en) 2014-09-25
EP3636251B1 (en) 2022-01-19
NI201500135A (es) 2016-03-16
PH12015502013B1 (en) 2016-01-11
KR102217616B1 (ko) 2021-02-19
CN105073096A (zh) 2015-11-18
KR20150132381A (ko) 2015-11-25
BR112015022972B1 (pt) 2023-02-14
EP2968122A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
CR20150480A (es) Composición farmacéutica de clorhidrato de s-cetamina
JO3452B1 (ar) بنزاميدات أمينو اريل مغاير كمثبطات كيناز
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
BR112015011430A2 (pt) composição para liberação imediata e prolongada
BR112015016930A2 (pt) formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
BR112013022213A2 (pt) administração parenteral de tapentadol
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
WO2014153009A3 (en) Thiosaccharide mucolytic agents
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112016024235A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
MX2016001422A (es) Composicion farmaceutica de fingolimod.
BR112017004948A2 (pt) formulação farmacêutica.
PH12016500577A1 (en) Piperazine derivatives and the use thereof as medicament
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina
BR112017014295A2 (pt) composição farmacêutica.
BR112016011999A2 (pt) Derivados de amida para agonista de gpr119
BR112016008704A8 (pt) derivados de indol-urea glucopiranosil-substituídos, composições farmacêuticas, e seus usos
BR112018012616A2 (pt) formulação galênica que compreende um fármaco tópico
BR112016024236A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
CU20160048A7 (es) Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2014, OBSERVADAS AS CONDICOES LEGAIS